Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis

Free Subscription Articles published in J Virol Retrieve available abstracts of 56 articles: HTML format

Single Articles

September 2025
1. MATSUI C, Yuliandari P, Deng L, Abe T, et al
   Hepatitis C virus NS3/4A protease cleaves SPG20, a key regulator of lipid droplet turnover, to promote lipid droplet formation.
   J Virol. 2025 Sep 23:e0089025. doi: 10.1128/jvi.00890.
   PubMed     Abstract available
   
   
   
2. DING Y, Li Q, Sha Y, Si R, et al
   Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment.
   J Virol. 2025 Sep 18:e0128025. doi: 10.1128/jvi.01280.
   PubMed     Abstract available
   
   
   
3. SAEED U, Kim J, Piracha ZZ, Kwon H, et al
   Retraction for Saeed et al., "Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner".
   J Virol. 2025 Sep 12:e0118725. doi: 10.1128/jvi.01187.
   PubMed    
   
   
   
4. PIRACHA ZZ, Kwon H, Saeed U, Kim J, et al
   Retraction for Piracha et al., "Sirtuin 2 Isoform 1 Enhances Hepatitis B Virus RNA Transcription and DNA Synthesis through the AKT/GSK-3beta/beta-Catenin Signaling Pathway".
   J Virol. 2025 Sep 12:e0118625. doi: 10.1128/jvi.01186.
   PubMed    
   
   
   
5. HAGA Y, Babu E P, Swiderska-Syn M, Reagan EK, et al
   Hepatitis C virus modified (S)E2(F442NYT)-mRNA-LNP candidate vaccine promotes helper CXCR5(+)T cells.
   J Virol. 2025 Sep 5:e0135525. doi: 10.1128/jvi.01355.
   PubMed     Abstract available
   
   
   
6. SCHWOERER MP, Carver S, Cafiero TR, Joyce B, et al
   Assessment of hepatitis C virus permissiveness in iteratively genetically humanized mice.
   J Virol. 2025 Sep 3:e0079325. doi: 10.1128/jvi.00793.
   PubMed     Abstract available
   
   
   August 2025
7. SHI Z, Tsuge M, Collier N, Takeuchi Y, et al
   Modeling of hepatitis B virus infection spread in primary human hepatocytes.
   J Virol. 2025 Aug 4:e0092725. doi: 10.1128/jvi.00927.
   PubMed     Abstract available
   
   
   June 2025
8. TRIPATHI SK, Li Y, Luo G
   Syndecan 2 proteoglycan serves as a hepatitis B virus cell attachment receptor.
   J Virol. 2025 Jun 26:e0079625. doi: 10.1128/jvi.00796.
   PubMed     Abstract available
   
   
   
9. REXHOUSE C, Bailey JT, Moshkani S, Cimino JL, et al
   High antigen burden drives CD8+ T cell dysfunction in a mouse model of chronic hepatitis B virus infection.
   J Virol. 2025 Jun 12:e0071125. doi: 10.1128/jvi.00711.
   PubMed     Abstract available
   
   
   
10. LI Y, Zheng X, Xie L, Kapustina M, et al
    Heat shock protein 90 chaperone activity is required for hepatitis A virus replication.
    J Virol. 2025 Jun 5:e0050225. doi: 10.1128/jvi.00502.
    PubMed     Abstract available
    
    
    April 2025
11. WU S, Chen Z, Zhang Z, Xu J, et al
    Ubiquitin-dependent proteasomal degradation of small hepatitis B virus surface antigen mediated by TRIM21 and antagonized by OTUD4.
    J Virol. 2025 Apr 25:e0230924. doi: 10.1128/jvi.02309.
    PubMed     Abstract available
    
    
    
12. YAN H, Peng B, He W, Zhong G, et al
    Correction for Yan et al., "Molecular Determinants of Hepatitis B and D Virus Entry Restriction in Mouse Sodium Taurocholate Cotransporting Polypeptide".
    J Virol. 2025 Apr 16:e0044525. doi: 10.1128/jvi.00445.
    PubMed    
    
    
    March 2025
13. CHEN F, Wettengel JM, Gegenfurtner F, Moosmuller J, et al
    Identification of NTCP animal orthologs supporting hepatitis B virus binding and infection.
    J Virol. 2025 Mar 5:e0183324. doi: 10.1128/jvi.01833.
    PubMed     Abstract available
    
    
    January 2025
14. NOGALES A, Alonso C, Moreno S, Lorenzo G, et al
    Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies.
    J Virol. 2025;99:e0178224.
    PubMed     Abstract available
    
    
    
15. YAN H, Liu C, Li Y, Tang S, et al
    The characterization and structural basis of a human broadly binding antibody to HBV core protein.
    J Virol. 2025;99:e0169424.
    PubMed     Abstract available
    
    
    
16. CHEN Z, Eggerman TL, Bocharov AV, Baranova IN, et al
    APOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B virus.
    J Virol. 2025 Jan 27:e0187924. doi: 10.1128/jvi.01879.
    PubMed     Abstract available
    
    
    
17. HUANG H-E, Colasanti O, Li T-F, Lohmann V, et al
    Limited impact of hepatitis A virus 3C protease-mediated cleavage on the functions of NEMO in human hepatocytes.
    J Virol. 2025 Jan 24:e0226424. doi: 10.1128/jvi.02264.
    PubMed     Abstract available
    
    
    
18. FEDORCHENKO SV, Klimenko Z, Martynovich T, Solianyk I, et al
    Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.
    J Virol. 2025 Jan 22:e0184324. doi: 10.1128/jvi.01843.
    PubMed     Abstract available
    
    
    November 2024
19. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed     Abstract available
    
    
    
20. KANG N, Liu N, Liu M, Zhang S, et al
    Identification and characterization of host factor VCPIP1 as a multi-functional positive regulator of hepatitis B virus.
    J Virol. 2024 Nov 4:e0158124. doi: 10.1128/jvi.01581.
    PubMed     Abstract available
    
    
    October 2024
21. WU Y, Ren L, Mao C, Shen Z, et al
    Small hepatitis B virus surface antigen (SHBs) induces dyslipidemia by suppressing apolipoprotein-AII expression through ER stress-mediated modulation of HNF4alpha and C/EBPgamma.
    J Virol. 2024 Oct 29:e0123924. doi: 10.1128/jvi.01239.
    PubMed     Abstract available
    
    
    
22. QUELLEC J, Piro-Megy C, Cannac M, Nisole S, et al
    Rift Valley fever virus is able to cross the human blood-brain barrier in vitro by direct infection with no deleterious effects.
    J Virol. 2024;98:e0126724.
    PubMed     Abstract available
    
    
    
23. MATRENEC R, Oropeza CE, Dekoven E, Matrenec C, et al
    Foxa deficiency restricts hepatitis B virus biosynthesis through epigenic silencing.
    J Virol. 2024 Oct 8:e0137124. doi: 10.1128/jvi.01371.
    PubMed     Abstract available
    
    
    
24. LI A, Zhao K, Duan Y, Zhang B, et al
    SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA transcription.
    J Virol. 2024 Oct 7:e0104224. doi: 10.1128/jvi.01042.
    PubMed     Abstract available
    
    
    September 2024
25. IBRAHIM MK, Liu C-D, Zhang L, Yu X, et al
    The loss of hepatitis B virus receptor NTCP/SLC10A1 in human liver cancer cells is due to epigenetic silencing.
    J Virol. 2024 Sep 19:e0118724. doi: 10.1128/jvi.01187.
    PubMed     Abstract available
    
    
    August 2024
26. LOWERY SA, Schuster N, Wong L-YR, Carrillo T Jr, et al
    Mouse hepatitis virus JHMV I protein is required for maximal virulence.
    J Virol. 2024 Aug 19:e0068024. doi: 10.1128/jvi.00680.
    PubMed     Abstract available
    
    
    July 2024
27. ZHANG J, Wang Q, Yuan W, Li J, et al
    Both middle and large envelope proteins can mediate neutralization of hepatitis B virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2 deletions.
    J Virol. 2024 Jul 30:e0192923. doi: 10.1128/jvi.01929.
    PubMed     Abstract available
    
    
    
28. MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al
    Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
    J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983.
    PubMed     Abstract available
    
    
    June 2024
29. HE Q, Liu T, Yang X, Yuan D, et al
    Optimization of immunosuppression strategies for the establishment of chronic hepatitis E virus infection in rabbits.
    J Virol. 2024 Jun 20:e0084624. doi: 10.1128/jvi.00846.
    PubMed     Abstract available
    
    
    
30. LIU J, Ito M, Liu L, Nakashima K, et al
    Involvement of ribosomal protein L17 and Y-box binding protein 1 in the assembly of hepatitis C virus potentially via their interaction with the 3' untranslated region of the viral genome.
    J Virol. 2024 Jun 20:e0052224. doi: 10.1128/jvi.00522.
    PubMed     Abstract available
    
    
    
31. WOYTINEK K, Glitscher M, Hildt E
    Antagonism of epidermal growth factor receptor signaling favors hepatitis E virus life cycle.
    J Virol. 2024 Jun 10:e0058024. doi: 10.1128/jvi.00580.
    PubMed     Abstract available
    
    
    May 2024
32. WON J, Kang HS, Kim NY, Dezhbord M, et al
    Tripartite motif-containing protein 21 is involved in IFN-gamma-induced suppression of hepatitis B virus by regulating hepatocyte nuclear factors.
    J Virol. 2024 May 23:e0046824. doi: 10.1128/jvi.00468.
    PubMed     Abstract available
    
    
    
33. PARONETTO O, Allioux C, Dimeglio C, Lobjois L, et al
    Characterization of virus?host recombinant variants of the hepatitis E virus.
    J Virol. 2024 May 7:e0029524. doi: 10.1128/jvi.00295.
    PubMed     Abstract available
    
    
    April 2024
34. SCHOLLMEIER A, Basic M, Glitscher M, Hildt E, et al
    The impact of HBx protein on mitochondrial dynamics and associated signaling pathways strongly depends on the hepatitis B virus genotype.
    J Virol. 2024 Apr 17:e0042424. doi: 10.1128/jvi.00424.
    PubMed     Abstract available
    
    
    March 2024
35. SHENG Y, Deng Y, Li X, Ji P, et al
    Hepatitis E virus ORF3 protein hijacking thioredoxin domain-containing protein 5 (TXNDC5) for its stability to promote viral particle release.
    J Virol. 2024 Mar 29:e0164923. doi: 10.1128/jvi.01649.
    PubMed     Abstract available
    
    
    
36. MCCOULLOUGH LC, Sadauskas T, Sozzi V, Mak KY, et al
    The in vitro replication phenotype of hepatitis B virus (HBV) splice variants Sp3 and Sp9 and their impact on wild-type HBV replication.
    J Virol. 2024 Mar 19:e0153823. doi: 10.1128/jvi.01538.
    PubMed     Abstract available
    
    
    
37. LI Y, Lemon SM
    Biochemical analysis of the host factor activity of ZCCHC14 in hepatitis A virus replication.
    J Virol. 2024 Mar 19:e0005724. doi: 10.1128/jvi.00057.
    PubMed     Abstract available
    
    
    
38. TAMURA T, Yamamoto H, Ogino S, Morioka Y, et al
    A rapid and versatile reverse genetics approach for generating recombinant positive-strand RNA viruses that use IRES-mediated translation.
    J Virol. 2024;98:e0163823.
    PubMed     Abstract available
    
    
    
39. BERKE JM, Tan Y, Sauviller S, Wu D-t, et al
    Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level in vivo is dependent on de novo core protein translation.
    J Virol. 2024;98:e0150223.
    PubMed     Abstract available
    
    
    February 2024
40. FRERICKS N, Brown RJP, Reinecke BM, Herrmann M, et al
    Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact on antiviral responses in primary human hepatocytes.
    J Virol. 2024 Feb 6:e0192123. doi: 10.1128/jvi.01921.
    PubMed     Abstract available
    
    
    
41. NAKAJIMA S, Watashi K, Kato T, Muramatsu M, et al
    Correction for Nakajima et al., "Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations".
    J Virol. 2024 Feb 2:e0182323. doi: 10.1128/jvi.01823.
    PubMed    
    
    
    January 2024
42. SHEN Z, Zhang S, Gao Z, Yu X, et al
    Intrahepatic homeobox protein MSX-1 is a novel host restriction factor of hepatitis B virus.
    J Virol. 2024 Jan 16:e0134523. doi: 10.1128/jvi.01345.
    PubMed     Abstract available
    
    
    
43. MATRENEC R, Oropeza CE, Dekoven E, Tarnow G, et al
    Ten-eleven translocation (Tet) methylcytosine dioxygenase-dependent viral DNA demethylation mediates in vivo hepatitis B virus (HBV) biosynthesis.
    J Virol. 2024 Jan 5:e0172123. doi: 10.1128/jvi.01721.
    PubMed     Abstract available
    
    
    
44. CASIANO MATOS J, Harichandran K, Tang J, Sviridov DO, et al
    Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.
    J Virol. 2024 Jan 4:e0084923. doi: 10.1128/jvi.00849.
    PubMed     Abstract available
    
    
    December 2023
45. HAGA Y, Meyer K, Sung MMH, Reagan EK, et al
    Hepatitis C virus modified sE2(F442NYT) as an antigen in candidate vaccine facilitates human immune cell activation.
    J Virol. 2023 Dec 12:e0180923. doi: 10.1128/jvi.01809.
    PubMed     Abstract available
    
    
    
46. GOBRAN ST, Pagliuzza A, Khedr O, Fert A, et al
    DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
    J Virol. 2023 Dec 5:e0110523. doi: 10.1128/jvi.01105.
    PubMed     Abstract available
    
    
    November 2023
47. BAJPAI PS, Collignon L, Solund C, Madsen LW, et al
    Full-length sequence analysis of hepatitis C virus genotype 3b strains and development of an in vivo infectious 3b cDNA clone.
    J Virol. 2023 Nov 21:e0092523. doi: 10.1128/jvi.00925.
    PubMed     Abstract available
    
    
    
48. XU X, Zhang L, Ye G, Shi J, et al
    Hepatitis B doubly spliced protein (HBDSP) promotes hepatocellular carcinoma cell apoptosis via ETS1/GATA2/YY1-mediated p53 transcription.
    J Virol. 2023 Nov 6:e0108723. doi: 10.1128/jvi.01087.
    PubMed     Abstract available
    
    
    October 2023
49. SEEGER C
    A CRISPR-based system to investigate HBV cccDNA biology.
    J Virol. 2023;97:e0118523.
    PubMed     Abstract available
    
    
    
50. VANRUSSELT H, Kum DB, Taverniti V, Liu C, et al
    Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles.
    J Virol. 2023;97:e0072223.
    PubMed     Abstract available
    
    
    
51. ARIFFIANTO A, Deng L, Abe T, Matsui C, et al
    Oxidative stress sensor Keap1 recognizes HBx protein to activate the Nrf2/ARE signaling pathway, thereby inhibiting hepatitis B virus replication.
    J Virol. 2023 Oct 6:e0128723. doi: 10.1128/jvi.01287.
    PubMed     Abstract available
    
    
    
52. LI Y, Yang Y, Li T, Wang Z, et al
    Activation of AIM2 by hepatitis B virus results in antiviral immunity that suppresses hepatitis C virus during coinfection.
    J Virol. 2023 Oct 3:e0109023. doi: 10.1128/jvi.01090.
    PubMed     Abstract available
    
    
    September 2023
53. NEPAL S, Holmstrom ED
    Single-molecule-binding studies of antivirals targeting the hepatitis C virus core protein.
    J Virol. 2023 Sep 29:e0089223. doi: 10.1128/jvi.00892.
    PubMed     Abstract available
    
    
    
54. XU L, Paine AC, Barbeau DJ, Alencastro F, et al
    Limiting viral replication in hepatocytes alters Rift Valley fever virus disease manifestations.
    J Virol. 2023;97:e0085323.
    PubMed     Abstract available
    
    
    
55. SHEN S, Liu W, Zeng G, Liang H, et al
    Conditional replication and secretion of hepatitis B virus genome uncover the truncated 3' terminus of encapsidated viral pregenomic RNA.
    J Virol. 2023 Sep 27:e0076023. doi: 10.1128/jvi.00760.
    PubMed     Abstract available
    
    
    
56. NAGASHIMA S, Primadharsini PP, Nishiyama T, Takahashi M, et al
    Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an antiviral drug screening platform.
    J Virol. 2023 Sep 8:e0050823. doi: 10.1128/jvi.00508.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.